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SCIENTIFIC OPINION 
Scientific Opinion on application (EFSA-GMO-NL-2007-39) for the placing 
on the market of insect resistant and herbicide tolerant genetically modified 
maize MON89034 x MON88017 for food and feed uses, import and 
processing under Regulation (EC) No 1829/2003 from Monsanto1 
EFSA Panel on Genetically Modified Organisms (GMO)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
 
This opinion, published on 27th May 2010, replaces the earlier version published on 30st March 20104. 
ABSTRACT 
This opinion reports on an evaluation of a risk assessment for placing on the market the genetically 
modified herbicide tolerant and insect resistant maize MON89034 x MON88017 for food and feed 
uses, import and processing. Conventional breeding methods were used in the production of maize 
MON89034 x MON88017 from inbred lines of the respective parental events. The structural integrity 
of the inserts in the single events as well as the phenotypes were retained in the hybrid. The expression 
levels of the Cry1A.105, Cry2Ab2, Cry3Bb1 and CP4 EPSPS proteins in maize MON89034 x 
MON88017 were demonstrated to be comparable with those of the single events. The comparative 
analysis of compositional, phenotypic and agronomic characteristics of this GM maize indicated 
equivalence with its conventional counterpart and commercial non-GM maize varieties except for the 
expression of the target proteins, providing resistance to certain lepidopteran and coleopteran pests and 
tolerance to glyphosate herbicide. The safety assessment identified no concerns regarding potential 
toxicity and allergenicity of maize MON89034 x MON88017. A feeding study on broiler chickens 
confirmed the nutritional equivalence of this GM maize to its conventional counterpart and 
commercial non-GM maize varieties. Considering the intended uses of maize MON89034 x 
MON88017, which excludes cultivation within the European Union, no scientific assessment of 
potential environmental effects associated with cultivation of maize MON89034 x MON88017 was 
required. In case of accidental release of viable maize grain of MON89034 x MON88017 into the 
                                                     
 
1  On request from the Competent Authority of the Netherlands on an application (EFSA-GMO-NL-2007-39) submitted by 
Monsanto, Question No EFSA-Q-2007-056, adopted on 10 March 2010. 
2  Panel members: Hans Christer Andersson, Salvatore Arpaia, Detlef Bartsch, Josep Casacuberta, Howard Davies, Patrick 
du Jardin, Gerhard Flachowsky, Lieve Herman, Huw Jones, Sirpa Kärenlampi, Jozsef Kiss, Gijs Kleter, Harry Kuiper, 
Antoine Messéan, Kaare Magne Nielsen, Joe Perry, Annette Pöting, Jeremy Sweet, Christoph Tebbe, Atte Johannes von 
Wright, and Jean-Michel Wal. Correspondence: gmo@efsa.europa.eu  
3 Acknowledgement: The EFSA GMO Panel wishes to thank the members of the Working Group on Molecular 
characterisation, Food and Feed and Environment for the preparation of this opinion, Ilona Kryspin-Sorensen as external 
expert and EFSA’s staff members Anna Christodoulidou, Karine Lheureux and Nancy Podevin for the support provided to 
this EFSA scientific output. 
4 In section References on page 25, the EFSA GMO Panel corrected the list of references (some references were not listed). 
The changes do not affect the overall conclusions of the scientific opinion. To avoid confusion, the original version of the 
scientific opinion has been removed from the website, but is available on request as is a version showing the changes made. 
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environment during transportation and processing, there are no indications of increased likelihood of 
establishment or survival of feral maize plants except in the presence of the glyphosate herbicides. In 
conclusion, the EFSA GMO Panel considers that the information available for maize MON89034 x 
MON88017 addresses the scientific comments raised by the Member States and that the maize 
MON89034 x MON88017 as described in this application is as safe as its conventional counterpart 
with respect to potential effects on human and animal health and the environment in the context of its 
intended uses. The EFSA GMO Panel concludes that maize event MON89034 x MON88017 is 
unlikely to have any adverse effect on human and animal health and the environment, in the context of 
its intended uses. 
 
KEY WORDS 
GMO, maize (Zea mays), maize MON89034 x MON88017, insect resistant, herbicide tolerant, risk assessment, 
food and feed safety, environment, import and processing, Regulation (EC) No 1829/2003. 
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SUMMARY 
Following the submission of an application (EFSA-GMO-NL-2007-39) under Regulation (EC) No 
1829/2003 from Monsanto, the Panel on Genetically Modified Organisms was asked to deliver a 
scientific opinion on herbicide tolerant and insect resistant genetically modified (GM) maize 
MON89034 x MON88017 (Unique identifier MON-89Ø34-3 × MON-88Ø17-3) for food and feed 
uses, import and processing. 
In delivering its scientific opinion, the EFSA GMO Panel considered the application EFSA-GMO-NL-
2007-39, additional information supplied by the applicant and scientific comments submitted by 
Member States. Further information from applications for placing the single events MON89034 and 
MON88017 on the market under EU regulatory procedures was taken into account where appropriate. 
The scope of application EFSA-GMO-NL-2007-39 is for food and feed uses, import and processing of 
maize MON89034 x MON88017 and all derived products, but excludes cultivation in the EU. The 
EFSA GMO Panel assessed maize MON89034 x MON88017 with reference to the intended uses and 
appropriate principles described in the Guidance Documents of the Scientific Panel on Genetically 
Modified Organisms for the risk assessment of genetically modified plants and derived food and feed 
and for the risk assessment of genetically modified plants containing stacked transformation events. 
The scientific assessment included molecular characterisation of the inserted DNA and expression of 
target proteins. A comparative analysis of agronomic traits and composition was undertaken, and the 
safety of the new protein and the whole food/feed were evaluated with respect to potential toxicity, 
allergenicity and nutritional quality. An assessment of environmental impacts and the post-market 
environmental monitoring plan were undertaken. 
Maize MON89034 and MON88017 have been developed for protection respectively against specific 
lepidopteran (Ostrinia nubilalis, Spodoptera spp., Agrotis ipsilon) and coleopteran (Diabrotica spp.) 
pests and for tolerance to glyphosate herbicides. Lepidopteran resistance is achieved by expression of 
the Cry1A.105 and Cry2Ab2 proteins derived from B. thuringiensis subsp. kurstaki in maize 
MON89034 and coleopteran resistance by expression of Cry3Bb1 protein from B. thuringiensis subsp. 
kumamotoensis) in maize MON88017, while tolerance to glyphosate is conferred by expression of 
CP4 EPSPS protein from a transgene derived from Agrobacterium tumefaciens (renamed Rhizobium 
radiobacter) strain CP4 in maize MON88017.  
Molecular analysis of the DNA present in maize MON89034 x MON88017 confirmed that maize 
MON89034 and MON88017 inserts are present and that their structures are retained. With regard to 
the expression of Cry1A.105, Cry2Ab2, Cry3Bb1, and CP4 EPSPS proteins, the overall protein levels 
were comparable between maize MON89034 x MON88017 and the respective single events. 
Based on results of the comparative analysis the EFSA GMO Panel concludes that maize MON89034 
x MON88017 is compositionally, phenotypically and agronomically equivalent to its conventional 
counterpart and commercial non-GM maize varieties, except for the presence of Cry1A.105, Cry2Ab2, 
Cry3Bb1 and CP4 EPSPS proteins in maize MON89034 x MON88017. Based on the assessment of 
data available, including the additional information provided by the applicant in response to the EFSA 
GMO Panel’s requests for maize MON89034 x MON88017, for the single events and for its 
conventional counterpart and commercial non-GM maize varieties, the EFSA GMO Panel has found 
no indication that crossing of MON89034 with MON88017 maize results in an interaction between the 
single events which causes compositional, phenotypic or agronomic changes. The Cry1A.105 and 
Cry2Ab2 expressed in the parental maize line MON89034 and the Cry3Bb1 and CP4 EPSPS proteins 
expressed in the parental maize line MON88017 have been assessed previously and no safety concerns 
were identified. Given all of the information provided, the EFSA GMO Panel concludes that there is 
no evidence for interactions between the single events that might impact on food and feed safety. The 
nutritional value of maize MON89034 x MON88017 has been investigated in a feeding study with 
broilers which confirmed that the nutritional properties of maize MON89034 x MON88017 would be 
no different from those of its conventional counterpart and commercial non-GM maize varieties.  
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The application EFSA-GMO-NL-2007-39 concerns food and feed uses, import and processing, but 
excludes cultivation in the EU. Therefore, there is no requirement for scientific assessment of possible 
environmental effects associated with the cultivation of maize MON89034 x MON88017. There are 
no indications of an increased likelihood of establishment and spread of feral maize plants in case of 
accidental release into the environment of viable maize MON89034 x MON88017 grains during 
transportation and processing for food and feed uses, except in the presence of glyphosate. Taking into 
account the scope of the application, both the rare occurrence of feral maize plants and the low levels 
of exposure through other routes indicate that the risk to non-target organisms is extremely low. The 
scope of the post-market environmental monitoring plan provided by the applicant is in line with the 
intended uses of maize MON89034 x MON88017. Furthermore, the EFSA GMO Panel agrees with 
the reporting intervals proposed by the applicant in the general surveillance plan. 
In conclusion, the EFSA GMO Panel considers that the information available for maize MON89034 x 
MON88017 addresses the scientific comments raised by the Member States and that the maize 
MON89034 x MON88017 as described in this application is as safe as its conventional counterpart 
with respect to potential effects on human and animal health and the environment in the context of its 
intended uses. The EFSA GMO Panel concludes that maize event MON89034 x MON88017 is 
unlikely to have any adverse effect on human and animal health and the environment, in the context of 
its intended uses. 
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BACKGROUND 48 
On 12/02/2007, the European Food Safety Authority (EFSA) received from the Competent Authority 49 
of The Netherlands an application (Reference EFSA-GMO-NL-2007-39), for authorisation of the 50 
insect resistant and herbicide tolerant genetically modified (GM) maize MON89034 x MON88017 51 
(Unique Identifier MON-89Ø34-3 × MON-88Ø17-3), submitted by Monsanto within the framework 52 
of Regulation (EC) No 1829/2003 on genetically modified food and feed. After receiving the 53 
application EFSA-GMO-NL-2007-39 and in accordance with Articles 5(2)(b) and 17(2)(b) of 54 
Regulation (EC) No 1829/2003, EFSA informed Member States and the European Commission, and 55 
made the summary of the application publicly available on the EFSA website. EFSA initiated a formal 56 
review of the application to check compliance with the requirements laid down in Articles 5(3) and 57 
17(3) of Regulation (EC) No 1829/2003. On 23/08/2007 and 11/09/2007, EFSA received additional 58 
information requested under completeness check (requested on 01/08/2007 and 05/09/2007 59 
respectively). On 20/09/2007, EFSA declared the application as valid in accordance with Articles 6(1) 60 
and 18(1) of Regulation (EC) No 1829/2003. 61 
EFSA made the valid application available to Member States and the European Commission, and 62 
consulted nominated risk assessment bodies of Member States, including national Competent 63 
Authorities within the meaning of Directive 2001/18/EC following the requirements of Articles 6(4) 64 
and 18(4) of Regulation (EC) No 1829/2003, to request their scientific opinion. Member State bodies 65 
had three months after the date of acknowledgement of the valid application (19/12/2007) within 66 
which to make their opinion known. 67 
The Scientific Panel on Genetically Modified Organisms of EFSA (EFSA GMO Panel) carried out a 68 
scientific assessment of the GM maize MON89034 x MON88017 for food and feed uses, import and 69 
processing in accordance with Articles 6(6) and 18(6) of Regulation (EC) No 1829/2003. When 70 
carrying out the safety assessment, the EFSA GMO Panel took into account the appropriate principles 71 
described in the Guidance Documents of the Scientific Panel on Genetically Modified Organisms for 72 
the risk assessment of genetically modified plants and derived food and feed (EFSA, 2006c) and for 73 
the risk assessment of genetically modified plants containing stacked transformation events (EFSA, 74 
2007), the scientific comments of Member States and the additional information provided by the 75 
applicant. Further information from applications for placing the single events MON89034 and 76 
MON88017 on the market under EU regulatory procedures was taken into account where appropriate.  77 
On 23/10/2007, 19/11/2007, 10/12/2007, 18/12/2008, 28/01/2009, 08/04/2009, 29/05/2009, 78 
30/06/2009, 05/11/2009, the EFSA GMO Panel requested from the applicant additional information. 79 
The applicant provided the requested information on 30/10/2007, 30/11/2007 and on 07/12/2007, 80 
17/04/2008 (spontaneously submitted), 06/10/2008, 08/01/2009, 19/02/2009, 03/06/2009, 30/06/2009, 81 
08/09/2009, 11/11/2009. After receipt and assessment of the full data package the EFSA GMO Panel 82 
finalised its risk assessment on maize MON89034 x MON88017. 83 
The single events MON89034 and MON88017 have been the subjects of earlier assessments and have 84 
received an EFSA scientific opinion in favour of their authorisation (EFSA, 2008, 2009a).  85 
In giving its scientific opinion on GM maize MON89034 x MON88017 to the European Commission, 86 
the Member States and the applicant, and in accordance with Articles 6(1) and 18(1) of Regulation 87 
(EC) No 1829/2003, EFSA has endeavoured to respect a time limit of six months from the 88 
acknowledgement of the valid application. As additional information was requested by the EFSA 89 
GMO Panel, the time limit of six months was extended accordingly, in line with Articles 6(1), 6(2), 90 
18(1), and 18(2) of Regulation (EC) No 1829/2003. 91 
According to Regulation (EC) No 1829/2003, this scientific opinion is to be seen as the report 92 
requested under Articles 6(6) and 18(6) of that Regulation and thus will be part of the EFSA overall 93 
opinion in accordance with Articles 6(5) and 18(5). 94 
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TERMS OF REFERENCE 95 
The EFSA GMO Panel was requested to carry out a scientific risk assessment of maize MON89034 x 96 
MON88017 for food and feed uses, import and processing in accordance with Articles 6(6) and 18(6) 97 
of Regulation (EC) No 1829/2003. Where applicable, any conditions or restrictions which should be 98 
imposed on the placing on the market and/or specific conditions or restrictions for use and handling, 99 
including post-market monitoring requirements based on the outcome of the risk assessment and, in 100 
the case of GMOs or food/feed containing or consisting of GMOs, conditions for the protection of 101 
particular ecosystems/environment and/or geographical areas should be indicated in accordance with 102 
Articles 6(5)(e) and 18(5)(e) of Regulation (EC) No 1829/2003.  103 
The EFSA GMO Panel was not requested to give a scientific opinion on information required under 104 
Annex II to the Cartagena Protocol. Furthermore, the EFSA GMO Panel did also not consider 105 
proposals for labelling and methods of detection (including sampling and the identification of the 106 
specific transformation event in the food/feed and/or food/feed produced from it), which are matters 107 
related to risk management. 108 
109 
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Assessment 110 
1. Introduction 111 
The genetically modified maize MON89034 x MON88017 (Unique Identifier MON-89Ø34-3 × 112 
MON-88Ø17-3) was assessed with reference to its intended uses, taking account of the appropriate 113 
principles described in the Guidance Documents of the Scientific Panel on Genetically Modified 114 
Organisms for the risk assessment of genetically modified plants and derived food and feed (EFSA, 115 
2006b) and for the risk assessment of genetically modified plants containing stacked transformation 116 
events (EFSA, 2006a). The risk assessment presented here is based on the information provided in the 117 
application relating to maize MON89034 x MON88017 submitted in the EU including additional 118 
information from the applicant and information on the single events, as well as scientific comments 119 
that were raised by the Member States. 120 
2. Issues raised by Member States 121 
The scientific comments raised by Member States are addressed in details in Annex G of the EFSA 122 
overall opinion5 and have been considered throughout this EFSA GMO Panel scientific opinion.  123 
3. Molecular characterisation 124 
3.1. Evaluation of relevant scientific data 125 
3.1.1. Method of production of maize MON89034 × MON88017  126 
Conventional breeding methods were used to produce maize MON89034 × MON88017 and no new 127 
genetic modification was involved. The two inserts that are present in maize MON89034 × 128 
MON88017 were derived from maize lines containing two independent events: MON89034 and 129 
MON88017. Each of these GM maize events was the subject of an earlier safety evaluation and 130 
separate opinions for each of them have been published (EFSA, 2008, 2009a). Maize MON89034 × 131 
MON88017 combines resistance to certain lepidopteran (Ostrinia nubilalis, Spodoptera spp., Agrotis 132 
ipsilon) and coleopteran (Diabrotica spp.) pests and tolerance to glyphosate-containing herbicides.  133 
3.1.2. Summary of the evaluation of the single events 134 
Maize MON89034  135 
Maize MON89034 was developed through Agrobacterium-mediated transformation using the binary 136 
plasmid vector PV-ZMIR245 containing two separate T-DNAs. The first T-DNA, designated as T-137 
DNA I, contains the cry1A.105 and the cry2Ab2 expression cassettes providing increased protection to 138 
lepidopteran pests such as European corn borer (Ostrinia nubilalis) fall armyworm (Spodoptera ssp.), 139 
black cutworm (Agrotis ipsilon) and corn earworm (Helicoverpa zea). The second T-DNA, designated 140 
as T-DNA II, contains the nptII expression cassette that encodes neomycin phosphotransferase that 141 
confers tolerance to certain antibiotics such as neomycin and kanamycin. The use of the two-T-DNA 142 
approach facilitates integration of the two different T-DNAs at genetic loci which can be segregated 143 
by breeding. Conventional breeding was used to isolate plants that contain the cry1A.105 and the 144 
cry2Ab2 expression cassettes (T-DNA I) but do not contain the nptII expression cassette (T-DNA II). 145 
This was confirmed by molecular analysis (EFSA, 2008).  146 
                                                     
 
5 http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2007-056 
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Molecular characterisation data established that MON89034 contains one copy of T-DNA I and that 147 
T-DNA II and vector backbone sequences are absent. The structure of the insert in maize MON89034 148 
was determined by Southern analysis and DNA sequencing. Data indicate that the Cauliflower mosaic 149 
virus e35S promoter that regulates expression of the cry1A.105 gene has been truncated and that the 150 
right border region of the T-DNA has been replaced by a left border region.  151 
Sequence comparison between the corresponding genomic region of conventional maize and the 152 
flanking regions of the maize MON89034 indicated that the pre-insertion locus was preserved except 153 
for the deletion of 57 bp and the addition of 10 bp. An updated bioinformatic analysis was performed 154 
(Tu and Silvanovich, 2009a, b). The data confirmed that no known endogenous maize coding 155 
sequences or regulatory sequences have been disrupted by the insert. Updated bioinformatic analysis 156 
also revealed no biologically relevant homologies to allergens or toxins for any of the putative 157 
polypeptides that might be produced from ORFs spanning the junction regions (Girault and McClain, 158 
2008; Tu and Silvanovich, 2009c, d, h).  159 
Southern analysis of maize MON89034 and maintenance of the phenotype indicated genetic and 160 
phenotypic stability of the event over multiple generations. 161 
Maize MON88017  162 
Maize MON88017 was developed through Agrobacterium-mediated transformation using the PV-163 
ZMIR39 plasmid and as a result expresses the modified B. thuringiensis (subsp. kumamotoensis) 164 
cry3Bb1 and CP4 epsps genes conferring resistance to coleopteran insect pests (Diabrotica spp.) and 165 
resulting in tolerance to glyphosate-containing herbicides, respectively. Molecular characterisation 166 
data established that MON88017 contains one copy of the T-DNA and that vector backbone sequences 167 
are absent (EFSA, 2009a).  168 
Similarity searches revealed that the flanking regions of the insert in maize MON88017 show 169 
significant level of identity to maize genomic DNA sequences and indicated that the pre-insertion 170 
locus was preserved except for the deletion of 26 bp and the addition of 20 bp. An updated 171 
bioinformatic analysis was performed (Tu and Silvanovich, 2009e, f). The data indicated that the 172 
insert is located approximately 100 bp upstream of a region corresponding to a maize full-length 173 
cDNA potentially coding for a protein with sequence similarity to putative purine permeases. This 174 
analysis confirmed previous bioinformatic analyses. Phenotypic, agronomic and compositional 175 
analyses showed that MON88017 is equivalent to conventional maize, except for the expected traits, 176 
indicating that the insertion of the transgene has not altered the expression of an essential gene that 177 
would raise a safety concern. Updated bioinformatic analysis also revealed no biologically relevant 178 
similarity to allergens or toxins for any of the putative peptides that might be produced from open 179 
reading frames spanning the junction regions (Girault et al., 2008; Tu and Silvanovich, 2009g, i).  180 
Southern analysis of MON88017 and maintenance of the phenotype indicated genetic and phenotypic 181 
stability of the event over multiple generations. 182 
3.1.3. Transgene constructs in maize MON89034 × MON88017 183 
Maize MON89034 × MON88017 has been obtained by conventional crossing of MON89034 and 184 
MON88017. No new genetic modification has been introduced in the stacked maize line. The integrity 185 
of the individual inserts present in this maize was investigated using Southern analyses. This involved 186 
the use of DNA probes specific for MON89034 and MON88017 inserts and restriction enzymes 187 
informative of the structure of both events, including the junctions with the host genomic DNA and 188 
confirmed the integrity of the single events when combined in maize MON89034 × MON88017.  189 
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3.1.4. Information on the expression of the inserts 190 
The levels of the newly expressed proteins Cry1A.105, Cry2Ab2, Cry3Bb1, and CP4 EPSPS in 191 
MON89034 × MON88017 were analysed by validated enzyme-linked immunosorbent assays 192 
(ELISA). Tissue samples for analysis were collected from five field trials conducted in USA during 193 
2005 (Hartmann et al., 2006, b). The trials were located within the major maize-growing regions of the 194 
USA and provided a variety of environmental conditions. At each site, maize MON89034 × 195 
MON88017, an appropriate conventional counterpart, MON89034 and MON88017 were planted 196 
using a randomized complete block design.  197 
The scope of the application covers food and feed uses and import and processing and excludes 198 
cultivation. Therefore protein expression data related to the grains are considered most relevant and 199 
are summarized in Table 1. Levels of proteins in the stacked line are comparable to those in the single 200 
events. 201 
Table 1: Summary of protein expression levels in maize MON89034 × MON88017, MON89034 and 202 
MON88017 grains (μg/g dry weight) 203 
 MON89034 x MON88017 MON89034 MON88017 
Cry1A.105 mean  
          range 
 5.6  
 [1.9-7.5] 
 5.8  
 [4.5-6.8] -- 
Cry2Ab2   mean  
           range 
1.3  
[0.8-1.9] 
1.3  
[0.8-1.9] -- 
Cry3Bb1   mean  
           range 
4.1  
[1.3-9.7] -- 
4.4  
[2.9-6.5] 
CP4 EPSPS mean  
           range 
3.4  
[2.2-4.7] -- 
3.3  
[1.8-4.8] 
 204 
3.1.5. Inheritance and stability of inserted DNA 205 
The genetic stability of the inserted DNA in events MON89034 and MON88017 was demonstrated 206 
previously (EFSA, 2008, 2009a). In maize MON89034 × MON88017 the two inserts are combined. 207 
The Southern analyses show that the integrity of the inserts present in the single events is retained in 208 
MON89034 × MON88017 (Groat et al., 2006). Furthermore, each of the traits has been conserved in 209 
this maize. 210 
3.2. Conclusion 211 
As conventional breeding methods were used in the production of maize MON89034 × MON88017, 212 
no additional genetic modification was involved. Southern analyses demonstrated that the structures of 213 
the MON89034 and MON88017 events were retained in maize MON89034 × MON88017.   214 
The expression levels of Cry1A.105, Cry2Ab2, Cry3Bb1, and CP4 EPSPS proteins in the grains of 215 
maize MON89034 × MON88017 have been demonstrated to be comparable with those of the single 216 
events.  217 
The EFSA GMO Panel concludes that the molecular characterisation of maize MON89034 x 218 
MON88017 does not indicate safety concerns. 219 
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4. Comparative analysis 220 
4.1. Evaluation of relevant scientific data 221 
4.1.1. Summary of the previous evaluation of the single events  222 
 223 
Maize MON89034 224 
Forage and grains of maize MON89034 and the same tissues from the conventional counterpart with a 225 
comparable genetic background were obtained from field trials carried out in the year 2004 in the USA 226 
and in the season 2004-2005 in Argentina. Both trials included five different locations representative 227 
of the respective geographical region. The trials used agronomic practices which were also 228 
representative of these regions. In addition to its conventional counterpart, a total of 15 commercial 229 
non-GM maize varieties were included in the field trial to estimate the naturally occurring variation in 230 
composition expected for the various analytes in conventional maize.  231 
With regard to agronomic and phenotypic characteristics no consistent differences were observed 232 
between maize MON89034 and its conventional counterpart grown in the various field trials. With 233 
regard to compositional analyses, statistical difference between MON89034 and its conventional 234 
counterpart were identified but were not consistent across the different trial sites. All of the observed 235 
differences were small and fell within the natural variation found in the commercial non-GM maize 236 
varieties grown at these sites. Furthermore, the composition of maize MON89034 fell within natural 237 
variation as reported in the literature and crop composition databases (ILSI, 2006). 238 
The EFSA GMO Panel concluded that maize MON89034 is equivalent to its conventional counterpart 239 
with regard to compositional, phenotypic and agronomic characteristics except for the expression of 240 
the target traits (EFSA, 2008). 241 
 242 
Maize MON88017 243 
Forage and grains of maize MON88017 plants sprayed with glyphosate and the same tissues from its 244 
conventional counterpart with a comparable genetic background were obtained from field trials carried 245 
out at three locations in the USA in 2002 and at four locations in Argentina in 2003-2004. Also 246 
commercial non-GM maize varieties were grown alongside maize MON88017 and its conventional 247 
counterpart in the same locations. The level of several compounds (vitamin B1, oleic acid, and linoleic 248 
acid) showed statistically significant differences between maize MON88017 and its conventional 249 
counterpart in the across-location and single site analysis during one of the seasons. However, these 250 
differences did not occur in the other season and were within the range of each constituent determined 251 
in non-GM varieties and/or obtained from historical data or information in the literature. Additional 252 
data from field trials in Europe were provided by the applicant at the request of the EFSA GMO Panel. 253 
In these cases, MON88017 not treated with glyphosate was grown at three locations in Germany and 254 
at three locations in Spain in 2007. Various statistically significant differences were observed between 255 
MON88017 and its conventional counterpart, none of which occurred within all locations and all of 256 
which were within the range of commercial non-GM maize varieties. Based on these data, the EFSA 257 
GMO Panel concluded that maize MON88017 is compositionally equivalent to its conventional 258 
counterpart and commercial non-GM maize varieties, except for the presence of Cry3Bb1 and CP4 259 
EPSPS proteins in maize MON88017 due to the genetic modification. 260 
No consistent differences were observed in the analysis of agronomic and phenotypic characteristics 261 
of MON88017 compared to its conventional counterpart and commercial non-GM maize varieties over 262 
several seasons and no consistent differences were observed in each season and at all locations. The 263 
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EFSA GMO Panel concluded that maize MON88017 is equivalent to its conventional counterpart and 264 
commercial non-GM maize varieties with regard to phenotypic characteristics and agronomic 265 
performance except for expression of the introduced trait (EFSA, 2009a). 266 
4.1.2. Choice of conventional counterpart and additional comparators and production of 267 
material for the compositional assessment 268 
The comparative compositional, phenotypic, and agronomic analysis of maize MON89034 x 269 
MON88017 and its conventional counterpart was performed in field trials at five locations in the USA 270 
in 2004. The combined event MON89034 x MON88017 had been obtained by crossing two inbred 271 
lines containing the single events MON89034 and MON88017. Also grown at the same locations were 272 
commercial non-GM maize varieties, three varieties at each location, amounting to a total of 15 273 
different varieties across locations. All replicates at the same location underwent similar agronomic 274 
treatments. From each replicate, samples of grains and forage were analyzed for composition. The 275 
grain samples were additionally checked for the presence or absence of recombinant DNA by PCR 276 
analysis.  277 
In the context of previous applications, analytical data on materials obtained from field trials with the 278 
single maize events (MON89034 and MON88017) and the respective appropriate conventional 279 
counterparts and commercial non-GM maize varieties were provided by the applicant (see section 280 
4.1.1). The EFSA GMO Panel previously evaluated these data and concluded that the maize events 281 
MON89034 and MON88017 (the latter treated and untreated with the respective target herbicide) were 282 
compositionally and agronomically equivalent to their respective conventional counterparts, except for 283 
the newly introduced traits (EFSA, 2008, 2009a). The EFSA GMO Panel noted the fact that treatment 284 
of the single maize event MON88017 with the target herbicide to which it is tolerant did not affect its 285 
agronomic and compositional characteristics compared to untreated maize MON88017 plants (EFSA, 286 
2009a). The EFSA GMO Panel, therefore, accepts the design of field trials with maize MON89034 x 287 
MON88017 without inclusion of the single events and treatment with the target herbicide.  288 
4.1.3. Compositional analysis 289 
The compositional analysis of maize forage included the following parameters: proximate (moisture, 290 
ash, total fat, crude protein; carbohydrates by calculation), fibre [acid detergent fibre (ADF) and 291 
neutral detergent fibre (NDF)], calcium, and phosphorus. Grains were additionally analyzed for total 292 
dietary fibre (TDF), amino acids, fatty acids, minerals, vitamins, and secondary metabolites (phytic 293 
acid, raffinose, furfuraldehyde, ferulic acid, and p-coumaric acid). The levels of these constituents 294 
found in maize MON89034 x MON88017, its conventional counterpart, and the commercial non-GM 295 
maize varieties, were also compared with background data on levels of these parameters reported in 296 
the literature and available in the ILSI Crop Composition database (ILSI, 2006). The across-location 297 
statistical analysis of the comparison between levels in maize MON89034 x MON88017 and its 298 
conventional counterpart showed that various parameters were statistically significantly different. In 299 
forage, the level of protein was higher in maize MON89034 x MON88017 than in its conventional 300 
counterpart. The level of protein was statistically significantly increased in grains, while carbohydrates 301 
were slightly decreased. In grains, also fifteen amino acids showed statistically significantly higher 302 
values for maize MON89034 x MON88017 as compared to its conventional counterpart if these values 303 
were calculated on a dry-weight basis. However, if calculations were based on the percentage of these 304 
amino acids as components of the total amino acid pool, no statistically significant differences could 305 
be observed in the comparison of amino acid values between maize MON89034 x MON88017 and its 306 
conventional counterpart. The EFSA GMO Panel therefore considers the elevated level of several 307 
amino acids on a dry-weight basis to be related to the increased level of protein. In grains, the fatty 308 
acid stearic acid occurred at a statistically significantly increased level, while the levels of oleic acid 309 
and eicosenoic acid were slightly decreased. Also levels of calcium, manganese, ferulic acid and p-310 
coumaric acid were statistically significantly increased in maize MON89034 x MON88017 as 311 
compared to its conventional counterpart. Various other constituents were statistically significantly 312 
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increased or reduced at single locations but not at all locations. Moreover, the average values showing 313 
these differences were within the ranges of commercial non-GM maize varieties and also within the 314 
background ranges published in the literature and a crop composition database (ILSI, 2006). The 315 
EFSA GMO Panel considered the observed compositional differences between maize MON89034 x 316 
MON88017 and its conventional counterpart in the light of the field trial design, biological variation 317 
and level of the studied compounds in commercial non-GM maize varieties, and concludes that maize 318 
MON89034 x MON88017 is compositionally equivalent to its conventional counterpart and 319 
commercial non-GM maize varieties except for the introduced traits. Given these outcomes and the 320 
fact that compositional data on the single events grown during multiple seasons have already shown 321 
these to be compositionally equivalent to their conventional counterparts and commercial non-GM 322 
maize varieties, the EFSA GMO Panel does consider the data from one season comparing maize 323 
MON89034 x MON88017 with its conventional counterpart and commercial non-GM maize varieties 324 
as sufficient. 325 
4.1.4. Agronomic traits and GM phenotype 326 
As previously mentioned in section 4.1.2, an analysis of the agronomic and phenotypic characteristics 327 
of maize MON89034 x MON88017, its conventional counterpart maize, and non-GM maize varieties 328 
were carried out during field trial at five locations in the USA in 2004. The following parameters, 329 
were measured and statistically analyzed: early stand count; seedling vigour; days to 50% silking; 330 
days to 50% pollen shed; plant height; ear height; staygreen; dropped ears; stalk lodging; root lodging; 331 
final stand count; grain moisture; test weight; and yield. In the statistical analysis, the outcomes for 332 
maize MON89034 x MON88017 were compared with those for its conventional counterpart. The 333 
outcomes for the commercial non-GM maize varieties were used to create a tolerance interval with 334 
which the results for maize MON89034 x MON88017 could be compared. In the overall statistical 335 
analysis of average values across locations, several small but statistically significant differences were 336 
observed between MON89034 x MON88017 and its conventional counterpart, including a higher 337 
number of days until 50% of the plants had developed silk, a lower number stalk-lodged plants, and a 338 
higher yield of grains in maize MON89034 x MON88017. None of the differences observed across 339 
locations occurred at each location. 340 
In the absence of consistent unexpected differences between the studied maize plants, the EFSA GMO 341 
Panel concluded that no agronomic differences specific for maize MON89034 x MON88017 as 342 
compared to its conventional counterpart and commercial non-GM maize varieties have been observed 343 
except for the introduced herbicide tolerance and insect resistance traits. 344 
4.2. Conclusion 345 
Based on the results of the comparative analysis, it is concluded that maize MON89034 x MON88017 346 
is compositionally and agronomically equivalent to its conventional counterpart and commercial non-347 
GM maize varieties, except for the presence of Cry1A.105, Cry2Ab2, Cry3Bb1 and CP4 EPSPS 348 
proteins in maize MON89034 x MON88017. Based on the assessment of the data available, the EFSA 349 
GMO Panel has found no indication that crossing maize MON89034 with MON88017 maize results in 350 
an interaction between the single events which causes compositional or agronomic changes. 351 
 352 
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5. Food/Feed safety assessment 353 
5.1. Evaluation of relevant scientific data 354 
5.1.1. Summary of the previous evaluation of the single events  355 
 356 
Maize MON89034 357 
Maize MON89034 expresses the Cry1A.105 and Cry2Ab2 proteins. Escherichia coli-produced 358 
Cry1A.105 and Cry2Ab2 proteins were used for safety studies after it had been demonstrated 359 
experimentally that they are equivalent to those that are present in maize event MON89034. No 360 
toxicity of the Cry1A.105 and Cry2Ab2 proteins were observed in acute oral toxicity studies in mice. 361 
Both proteins were shown to be quickly degraded in simulated gastric fluid, and a little less quickly in 362 
simulated intestinal fluid. In bioinformatics studies, the amino acid sequence of Cry1A.105 and 363 
Cry2Ab2 showed no similarity either to proteins that are known to be toxic to humans and other 364 
mammals or to allergens. In a 90-day feeding study in rats with grain material from maize 365 
MON89034, no treatment-related adverse effects were observed, and a 42-day feeding study on broiler 366 
chickens showed that maize MON89034 is nutritionally equivalent to its conventional counterpart and 367 
commercial non-GM maize varieties included in the study.  368 
It was concluded that maize MON89034 is as safe as conventional maize and that the overall 369 
allergenicity of the whole plant is not changed. Maize MON89034 and derived products are unlikely 370 
to have any adverse effects on human and animal health in the context of its intended use (EFSA, 371 
2008). 372 
 373 
Maize MON88017 374 
Analogues of the newly expressed Cry3Bb1 and CP4 EPSPS proteins in MON88017 maize were 375 
obtained from recombinant strains of E. coli and used for safety testing after their equivalence to the 376 
plant-expressed proteins had been demonstrated experimentally. Neither proteins showed toxicity in 377 
acute oral toxicity studies in mice, nor did they show relevant similarities to known toxic or allergenic 378 
proteins in bioinformatics-supported comparisons of their amino acid sequences. Cry3Bb1 and CP4 379 
EPSPS proteins were also rapidly degraded during incubations with simulated gastric fluid containing 380 
the digestive enzyme pepsin. 381 
The safety of the whole food/feed derived from MON88017 was tested in a 90 day rat feeding study 382 
with diets containing 33% grains from maize MON88017. No indications of adverse effects were 383 
observed in this study. Also a nutritional, 42-day broiler chicken feeding study was carried out with 384 
diets containing between 55 and 60% grains from maize MON88017, showing that the latter was 385 
nutritionally equivalent to conventional maize (EFSA, 2009a). 386 
The GMO Panel concluded that maize MON88017 is as safe as its conventional counterpart and 387 
commercial non-GM maize varieties and considered it unlikely that the overall allergenicity of the 388 
whole plant is changed. Maize MON88017 and derived products are unlikely to have any adverse 389 
effect on human and animal health in the context of the intended uses (EFSA, 2009a).  390 
5.1.2. Product description and intended use 391 
The scope of application EFSA-GMO-NL-2007-39 includes the import and processing of maize 392 
MON89034 x MON88017 and its derived products for use as food and feed. Thus, the possible uses of 393 
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maize MON89034 x MON88017 include the production of animal feed, but it also includes food 394 
products such as, starch, syrups and oils. 395 
Maize MON89034 x MON88017 is intended to improve agronomic performance only and is not 396 
intended to influence the nutritional properties, processing characteristics and overall use of maize as a 397 
crop. 398 
5.1.3. Effect of processing 399 
Since maize MON89034 x MON88017 is compositionally equivalent to its conventional counterpart 400 
(see Section 4.2), except for the newly expressed proteins, the effect of processing on maize 401 
MON89034 x MON88017 is not expected to be different compared to that on conventional maize. 402 
5.1.4. Toxicology 403 
5.1.4.1. Toxicological assessment of expressed novel proteins in MON89034 x MON88017 404 
As summarized in section 5.1.1, the EFSA GMO Panel has previously evaluated the safety of 405 
the newly expressed Cry1A.105, Cry2Ab2, Cry3Bb1, and CP4 EPSPS proteins, which are 406 
present in maize MON89034 x MON88017, and for which the EFSA GMO Panel has not 407 
identified any safety concern (EFSA, 2008, 2009a). In its evaluations of the safety of the 408 
single events MON89034 and MON88017, the EFSA GMO Panel considered a range of data 409 
on these newly expressed proteins, including their resistance to in-vitro degradation by 410 
proteolytic enzymes, acute toxicity studies, and similarity of the amino acid sequences of 411 
these proteins to those of known toxins based on bioinformatics-supported sequence 412 
comparisons. At the request of the EFSA GMO Panel, the applicant provided results of 413 
updated bioinformatic comparisons of the Cry1A105, Cry2Ab2, Cry3Bb1 and CP4 EPSPS 414 
with known toxic proteins for the current evaluation. The outcomes of these bioinformatics-415 
supported comparisons did not show any relevant similarities. In addition, the EFSA GMO 416 
Panel is not aware of any other new information that would change the conclusions of its 417 
previous opinions. Based on the known function and mode of action of the newly expressed 418 
proteins Cry1A.105, Cry2Ab2, Cry3Bb1, and CP4 EPSPS, the EFSA GMO Panel considers 419 
the occurrence of interactions among these proteins unlikely.  420 
5.1.4.2. Toxicological assessment of new constituents other than proteins 421 
No new constituents besides the Cry1A.105, Cry2Ab2, Cry3Bb1, and CP4 EPSPS proteins are 422 
expressed in maize MON89034 x MON88017. Moreover, in the compositional analysis of this maize, 423 
no relevant changes in its composition were detected. 424 
5.1.4.3. Toxicological assessment of the whole GM food/feed 425 
As described in the summaries of the EFSA’s GMO Panel’s previous assessments of the single maize 426 
events MON89034 and MON88017 (see section 5.1.1), the EFSA GMO Panel also considered the 427 
outcomes of 90-day rat feeding studies with grains of these events. No adverse effects were observed 428 
in these studies. The EFSA GMO Panel also found, in more general terms, these single events to be 429 
safe for human and animal consumption. No new genes in addition to those present in the parental 430 
maize varieties have been introduced in maize MON89034 x MON88017. In the current assessment, 431 
neither the structural integrity of the insert in maize MON89034 x MON88017 maize nor the protein 432 
expression levels have been found to be changed in comparison to the single events MON89034 and 433 
MON88017 (section 3.2). Moreover, the composition of maize MON89034 x MON88107 has been 434 
found to be equivalent to its conventional counterpart and commercial non-GM maize varieties 435 
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(section 4.1.3). The EFSA GMO Panel considered all the data available for maize MON89034 x 436 
MON88017, and the newly expressed proteins Cry1A.105, Cry2Ab2, Cry3Bb1, and CP4 EPSPS, and 437 
is of the opinion that interactions between the single maize events that might impact on the food and 438 
feed safety of maize MON89034 x MON88017 are unlikely.  439 
Therefore, the EFSA GMO Panel does not consider additional animal safety studies with the whole 440 
GM food/feed necessary. 441 
5.1.5. Allergenicity 442 
The strategies used when assessing the potential allergenic risk focus on the characterisation of the 443 
source of the recombinant protein, the potential of the newly expressed protein to induce sensitisation 444 
or to elicit allergic reactions in already sensitised persons and whether the transformation may have 445 
altered the allergenic properties of the modified food. A weight-of-evidence approach is 446 
recommended, taking into account all of the information obtained with various test methods, since no 447 
single experimental method yields decisive evidence for allergenicity (CAC, 2003; EFSA, 2006). 448 
5.1.5.1. Assessment of allergenicity of the newly expressed proteins 449 
The proteins Cry1A.105, Cry2Ab2, Cry3Bb1, and CP4 EPSPS in maize MON89034 x MON88017 450 
have been evaluated previously and it was found unlikely that they are allergenic (EFSA, 2008). At 451 
the request of the EFSA GMO Panel, the applicant submitted new bioinformatics-supported 452 
comparisons of the amino acid sequences of the proteins Cry1A.105, Cry2Ab2, Cry3Bb1, and CP4 453 
EPSPS with the sequences of known allergens using an updated version of the FARRP Allergen 454 
database. Based on the information provided, the EFSA GMO Panel considers it unlikely that 455 
potential interactions occur that might change the allergenicity of the newly expressed proteins. 456 
5.1.5.2. Assessment of allergenicity of the whole GM plant 457 
The issue of a potential increased allergenicity of maize MON89034 x MON88017, as compared to 458 
the single maize events MON89034 and MON88017, and to conventional maize varieties, does not 459 
appear relevant to the EFSA GMO Panel since maize is not considered a common allergenic food. 460 
However rare cases of occupational allergy to maize dust have been reported in the literature. The 461 
EFSA GMO Panel is also aware that few cases of food allergy to maize have been specifically 462 
observed in some geographically restricted areas where maize is a particular common food and that, in 463 
the few cases reported, the major maize allergens have then been identified. In the context of the 464 
present application the EFSA GMO Panel considers it unlikely that any interactions between the 465 
newly expressed proteins and metabolic pathways of maize would alter the pattern of expression of 466 
endogenous proteins/potential allergens and thereby significantly change the overall allergenicity of 467 
the whole plant. In addition, given all the available information, the EFSA GMO Panel sees no reason 468 
to expect that the use of GM maize MON89034 x MON88017 would significantly increase the intake 469 
and exposure to maize. 470 
5.1.6. Nutritional assessment of GM food/feed 471 
For each of the single events MON89034 and MON88017, the EFSA GMO Panel has previously 472 
assessed data on nutritional feeding studies in food-producing animals, in particular the rapidly 473 
growing chicken broiler (see section 5.1.1). The EFSA GMO Panel has thus concluded that the 474 
outcomes of these tests confirm the nutritional equivalence of the single events to conventional maize.  475 
In addition, the outcomes of a 42-day feeding study with maize MON89034 x MON88017 in chicken 476 
were provided in the frame of the current application. Groups of 100 chickens (50 males and 50 477 
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females) each received one of six maize-containing diets, i.e. with maize MON89034 x MON88017, 478 
its conventional counterpart and four commercial non-GM maize varieties. Each group had been 479 
subdivided into ten pens of ten animals per pen, with five pens each for male and female, adding up to 480 
50 animals per sex within each group of 100 animals. The content of maize in the diets varied between 481 
55% maize in starter diets to 59% in grower/finisher diets. Whilst maize grains and diets were 482 
analyzed for chemical composition, the grains were also analyzed for potential presence of pesticide 483 
and mycotoxin residues, and for the presence of transgenic DNA using PCR analysis. The 484 
measurements that were performed during the feeding experiment included the feed consumption, 485 
body weight, morbidity, and mortality of the animals. After the experiment, the animals were analyzed 486 
post-mortem for carcass characteristics, including the weights of the carcass and various carcass parts, 487 
as well as the composition of the meat of thighs and breast (fat, moisture, protein). Following a request 488 
from the EFSA GMO Panel the applicant has performed a direct comparison of the test and control 489 
chicken for each observed parameter. No statistically significant differences for the tested parameters 490 
were observed between the group fed maize MON89034 x MON88017 and its conventional 491 
counterpart, apart from a minor but statistically significant difference in relative (%) breast weights for 492 
which female chicken fed maize MON89034 x MON88017 showed a higher value than animals fed 493 
the control diet. Additional, small statistically significant differences were observed in thigh protein in 494 
females and breast moisture in males. The difference in relative breast weight was not observed in 495 
absolute breast weights. In the absence of any other treatment-related effects on performance, the 496 
EFSA GMO Panel does not consider these statistically significant differences to be of biological 497 
relevance. The EFSA GMO Panel concludes that the results of this 42-days chicken feeding study 498 
show that maize MON89034 x MON88017 is nutritionally equivalent to its conventional counterpart 499 
and commercial non-GM maize varieties.  500 
5.1.7. Post-market monitoring of GM food/feed 501 
The risk assessment concluded that no data have emerged to indicate that maize MON89034 x 502 
MON88017 is any less safe than its conventional counterpart. In addition, maize MON89034 x 503 
MON88017 is, from a nutritional point of view, substantially equivalent to commercial non-GM 504 
maize. Therefore, and in line with the Guidance document (EFSA, 2006), the EFSA GMO Panel is of 505 
the opinion that post-market monitoring of the GM food/feed is not necessary. 506 
5.2. Conclusion 507 
The Cry1A.105, Cry2Ab2, Cry3Bb1, and CP4 EPSPS proteins that are newly expressed in maize 508 
MON89034 x MON88017 have previously been assessed for their safety by the EFSA GMO Panel, as 509 
summarized in its previously published opinions on the single events MON89034 and MON88017. 510 
During these previous assessments, no adverse effects of these newly expressed proteins have been 511 
identified. In addition, the EFSA GMO Panel considers it unlikely that interactions among the newly 512 
expressed proteins will occur that may impact on the food and feed safety of maize MON89034 x 513 
MON88017. The EFSA GMO Panel bases its consideration on the data on the functional 514 
characteristics of these proteins, as well as the outcomes of the comparative analysis of compositional, 515 
phenotypic, agronomic and nutritional characteristics of the maize MON89034 x MON88017.  516 
Besides the newly expressed proteins, the safety and nutritional properties of whole food and feed 517 
products derived from MON89034 x MON88017 have also been considered. Maize MON89034 x 518 
MON88017 was tested in a nutritional chicken feeding study, which shows that this maize is 519 
nutritionally equivalent to its conventional counterpart and commercial non-GM maize varieties. The 520 
EFSA GMO Panel concludes that the outcomes of the chicken feeding study further support the 521 
findings of the comparative analysis of composition confirming the nutritional equivalence of maize 522 
MON89034 x MON88017 to conventional counterpart and commercial non-GM maize varieties. The 523 
EFSA GMO Panel also considers that it is unlikely that the overall allergenicity of maize MON89034 524 
x MON88017 has been altered. The EFSA GMO Panel is of the opinion that MON89034 x 525 
MON88017 is as safe as its conventional counterpart and commercial non-GM maize varieties, and 526 
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concludes that this maize and derived products are unlikely to have any adverse effects on human and 527 
animal health in the context of its intended use. 528 
 529 
6. Environmental risk assessment and monitoring 530 
6.1. Evaluation of relevant scientific data 531 
The scope of the application is for food and feed uses, import and processing of maize MON89034 x 532 
MON88017 and does not include cultivation. Considering the proposed uses of maize MON89034 x 533 
MON88017, the environmental risk assessment is concerned with the exposure through manure and 534 
faeces from gastrointestinal tracts of animals fed maize MON89034 x MON88017 and with the 535 
accidental release into the environment of maize MON89034 x MON88017 grains during 536 
transportation and processing.  537 
As the scope of the present application excludes cultivation, environmental concerns related to the use 538 
of glyphosate herbicides on maize MON89034 x MON88017 apply only to imported and processed 539 
maize products that may have been treated with those herbicides in countries of origin. The EFSA 540 
GMO Panel is aware that the risk assessment of active substances falls within the scope of Directive 541 
91/414/EEC concerning the placing of plant protection products on the market. 542 
6.1.1. Evaluation of the single events MON88017 and MON89034  543 
In its previous scientific opinions, the EFSA GMO Panel was of the opinion that both the single maize 544 
events MON89034 and MON88017 assessed in their respective applications as safe as their 545 
conventional counterpart and that the placing on the market of maize MON89034 and MON88017, for 546 
import and processing for food and feed uses, is unlikely to have an adverse effect on human or animal 547 
health, or on the environment (EFSA, 2008, 2009a). Furthermore, post-market environmental 548 
monitoring plans for MON89034 and MON88017, including general surveillance, were proposed by 549 
the applicant and considered in line with EFSA GMO Panel opinion on post-market environmental 550 
monitoring (EFSA, 2008, 2009a).  551 
 552 
6.1.2. Environmental risk assessment 553 
6.1.2.1. Unintended effects on plant fitness due to the genetic modification 554 
Maize is highly domesticated and generally unable to survive in the environment without cultivation. 555 
Maize plants are not winter hardy in many regions of Europe, they have lost their ability to release 556 
seeds from the cob and they do not occur outside cultivated land or disturbed habitats in agricultural 557 
landscapes of Europe, despite cultivation for many years. In cultivation, grains shed during harvest 558 
may survive overwinter in some milder regions, germinate and appear as volunteers in subsequent 559 
crops. The occurrence of maize volunteers was reported in Spain and other European regions (Gruber 560 
et al., 2008) and many of them grow weakly and flower asynchronously with the maize crop 561 
(Palaudelmàs et al., 2009).  562 
Applicant’s field trials have shown that there are no indications of an altered fitness of the single 563 
maize events MON88017 and MON89034 as compared to their conventional counterparts. In addition 564 
to the field trials carried out with the single events MON88017 and MON89034 (EFSA, 2008, 2009a), 565 
a series of field trials with maize MON89034 x MON88017 were conducted across 5 USA locations in 566 
2004. Information on 14 phenotypic and agronomic characteristics was provided to assess agronomic 567 
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performance of maize MON89034 x MON88017 in comparison with its conventional counterpart. 568 
These field trial data did not show changes in plant characteristics that indicate altered fitness and 569 
invasiveness of maize MON89034 x MON88017. In addition to the data presented by the applicant, 570 
the EFSA GMO Panel is not aware of any scientific report that would indicate the potential for 571 
increased establishment and spread of maize MON89034 x MON88017 and any change in survival 572 
capacity, including over-wintering.  573 
The herbicide tolerance trait can only be regarded as providing an agronomic advantage for this GM 574 
maize MON89034 x MON88017 plant where and when glyphosate herbicides are applied. Similarly 575 
insect resistance against certain lepidopteran and coleopteran target pests provides a potential 576 
advantage in cultivation under infestation of target pests. However survival of maize plants outside 577 
cultivation or other areas where glyphosate herbicides could be applied in Europe is mainly limited by 578 
a combination of low competitiveness, absence of a dormancy phase, and susceptibility to plant 579 
pathogens, herbivores and cold climatic conditions. Since these general characteristics are unchanged 580 
in maize MON89034 x MON88017, herbicide tolerance and insect resistance are not likely to provide 581 
a selective advantage outside cultivation in Europe. Therefore it is considered very unlikely that maize 582 
MON89034 x MON88017 will differ from conventional maize varieties in their ability to survive until 583 
subsequent seasons or to establish feral populations under European environmental conditions. 584 
Since maize MON89034 x MON88017 has no altered survival, multiplication or dissemination 585 
characteristics, except when glyphosate herbicides are applied and/or under infestation of target pests, 586 
the EFSA GMO Panel is of the opinion that the likelihood of unintended environmental effects due to 587 
the accidental release into the environment of viable maize MON89034 x MON88017 grains will not 588 
differ from that of the single events maize MON88017 or MON89034 or from that of conventional 589 
maize varieties.  590 
6.1.2.2. Potential for gene transfer 591 
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic material, 592 
either through horizontal gene transfer of DNA, or vertical gene flow via seed dispersal and cross-593 
pollination. 594 
 595 
 596 
(a) Plant to bacteria gene transfer  597 
Genomic DNA is a component of many food and feed products derived from maize. It is well 598 
documented that DNA present in food and feed becomes substantially degraded in the process of 599 
digestion in the human or animal gastrointestinal tract. However, a low level of exposure of fragments 600 
of ingested DNA, including the recombinant fraction of such DNA, to micro-organisms in the 601 
digestive tract of humans, domesticated animals, and other animals feeding on maize MON89034 x 602 
MON88017 is expected (see section 5 of the scientific opinion).  603 
Current scientific knowledge indicates that horizontal gene transfer of non-mobile DNA fragments 604 
between unrelated organisms (such as plants to micro-organisms) is extremely unlikely to occur under 605 
natural conditions (see EFSA, 2009bfor further details). In addition to the low concentration of DNA 606 
in the gastrointestinal tract and the lack of competence of most bacteria to take up foreign DNA, the 607 
major barrier to such horizontal transfer is the lack of sufficient DNA sequence similarity for 608 
homologous recombination to occur in bacteria.  609 
The cry1A.105, cry2Ab2, cry3Bb1 and CP4 epsps genes are of bacterial origin. Thus, in theory, the 610 
cry1A.105, cry2Ab2, cry3Bb1 and CP4 epsps genes of the recombinant DNA insert could provide 611 
sufficient DNA similarity for homologous recombination with genes from environmental bacteria. 612 
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However, such hypothesized horizontal gene transfer event is not likely to be maintained in bacterial 613 
populations due to a predicted lack of efficient expression and no identified selective advantage for 614 
gene transfer recipients in the unlikely case of their expression.  615 
In case of illegitimate recombination into genomes of bacteria in the environment, it is unlikely that 616 
recombinant genes (CP4 epsps) regulated by eukaryotic plant promoters in maize MON89034 x 617 
MON88017 would be expressed. The cry1A.105, cry2Ab2 and cry3Bb1 genes are regulated by plant 618 
virus promoters. The activity of these plant virus promoters in unrelated organisms such as bacteria 619 
cannot be excluded but in the unlikely event that the above mentioned genes and regulatory elements 620 
are taken up by bacteria, no selective advantage is anticipated because cry and CP4 epsps genes are 621 
distributed in various bacterial species in the natural environment. Thus, the hypothesized low level 622 
exposure of bacterial communities in the environment to the maize MON89034 x MON88017 623 
cry1A.105, cry2Ab2, cry3Bb1and CP4 epsps genes must be seen in the context of the natural 624 
occurrence and level of exposure to alternative sources of genetically diverse cry and epsps genes to 625 
which bacterial communities are naturally exposed.  626 
The wide environmental presence of genetically diverse natural variants of the recombinant DNA 627 
coding sequences, the use of regulatory sequences optimised for expression in eukaryotes, and the 628 
absence of an identified plausible selective advantage, suggest it is highly unlikely that the 629 
recombinant DNA will transfer and establish in the genome of bacteria in the environment or human 630 
and animal digestive tract.  631 
(b) Plant to plant gene transfer 632 
The extent of cross-pollination of other maize varieties will mainly depend upon the scale of 633 
accidental release during transportation and processing, and the successful establishment and 634 
subsequent flowering of this GM maize plant. For maize, any vertical gene transfer is limited to other 635 
Zea mays plants as populations of sexually compatible wild relatives of maize are not known in 636 
Europe (Eastham and Sweet, 2002, OECD, 2003).  637 
The flowering of occasional GM maize plants originating from accidental release occurring during 638 
transportation and processing is unlikely to disperse significant amounts of GM maize pollen to other 639 
maize plants. Field observations performed on maize volunteers after GM maize cultivation in Spain 640 
revealed that maize volunteers had a low vigour, rarely had cobs and produced pollen that cross-641 
pollinated neighbour plants only at low levels (Palaudelmàs et al., 2009). 642 
Herbicide tolerance and insect resistance provide agronomic and selective advantages in areas where 643 
glyphosate herbicides are applied and/or under infestation of target pests. Even though the occurrence 644 
of some GM maize plants outside cropped area have been reported in Korea due to grain spillage 645 
during import, transportation, storage, handling and processing (Kim CG et al., 2006, Lee et al., 2009, 646 
Park KW et al., 2009), survival of maize plants outside cultivation in Europe is mainly limited by a 647 
combination of low competitiveness, absence of a dormancy phase, and susceptibility to plant 648 
pathogens and frost. Since these general characteristics are unchanged in maize MON89034 x 649 
MON88017, herbicide tolerance and insect resistance are not likely to provide selective advantages 650 
outside cultivation or other areas where glyphosate herbicides could be applied and/or under 651 
infestation of target pests in Europe. Therefore, as for any other maize varieties, these GM maize 652 
plants would only survive in subsequent seasons in warmer regions of Europe and are not likely to 653 
establish feral populations under European environmental conditions. 654 
In conclusion, maize MON89034 x MON88017 has no altered survival, multiplication or 655 
dissemination characteristics except when glyphosate herbicides are applied, and/or under infestation 656 
of target pests. The EFSA GMO Panel is of the opinion that the likelihood of unintended 657 
environmental effects as a consequence of spread of genes from this maize in Europe will not differ 658 
from that of the single maize events MON88017 and MON89034, or of other conventional maize 659 
Scientific opinion on insect resistant and herbicide tolerant GM maize 
MON89034 x MON88017 for food and feed uses, import and processing 
 
 
21 EFSA Journal 2010; 8(3):1564 
varieties and considers that maize MON89034 x MON88017 is unlikely to cause adverse effects, in 660 
the context of the intended uses. 661 
6.1.2.3. Interactions of the GM plant with target organisms  662 
The intended uses of maize MON89034 x MON88017 specifically exclude cultivation and the 663 
environmental exposure of target organisms to maize MON89034 x MON88017 plants is limited to 664 
the accidental release of viable grains into the environment during transportation and processing. The 665 
EFSA GMO Panel considers that it would need successful establishment and spread of high numbers 666 
of maize MON89034 x MON88017 plants to enable any significant interaction with target organisms, 667 
which is very unlikely. 668 
6.1.2.4. Interactions of the GM plant with non-target organisms 669 
The intended uses of maize MON89034 x MON88017 specifically exclude cultivation so that 670 
environmental exposure of non-target organisms to maize MON89034 x MON88017 plants is limited 671 
to the accidental release of viable grains into the environment during transportation and processing. 672 
The EFSA GMO Panel considers that it would need successful establishment and spread of high 673 
numbers of maize MON89034 x MON88017 plants to enable any significant interaction with non-674 
target organisms, which is very unlikely. 675 
In addition, the EFSA GMO Panel evaluated whether the Cry1A.105, Cry2Ab2 and Cry3Bb1 proteins 676 
might potentially affect non-target organisms by entering the environment through manure and faeces 677 
from the gastrointestinal tracts of animals fed maize MON89034 x MON88017. Due to the specific 678 
insecticidal selectivity of the Cry proteins, non-target organisms most likely to be affected by the 679 
Cry1A.105, Cry2Ab2 and Cry3Bb1 proteins belong to the same or closely related taxonomic groups 680 
as those of the target organisms.  681 
Data supplied by the applicant suggest that only very low amounts of the Cry1A.105, Cry2Ab2 and 682 
Cry3Bb1 proteins enter the environment due to low expression in grains. Moreover, these Cry proteins 683 
are degraded by enzymatic activity in the gastrointestinal tract of animals fed GM maize or derived 684 
feed products (see section 5.1.1), meaning that only low amounts of these proteins would remain intact 685 
to pass out in faeces. This has been demonstrated for Cry1Ab (Einspanier et al., 2004, Ahmad et al., 686 
2005, Lutz et al., 2005, Lutz et al., 2006, Wiedemann et al., 2006, Guertler et al., 2008, Paul et al., 687 
2010). It is expected that there would subsequently be further degradation of Cry proteins in the 688 
manure and faeces due to intrinsic microbial proteolytic activity. Therefore, exposure of soil and 689 
aquatic environments to the Cry1A.105, Cry2Ab2 and Cry3Bb1 proteins from disposal of animal 690 
wastes or accidental spillage of maize grains is likely to be very low and localized. While Cry proteins 691 
may bind to a certain degree to clay minerals or humic substances in soil, thereby reducing their 692 
availability to micro-organisms for degradation, there are no indications of persistence and 693 
accumulation of Cry proteins from GM crops in soil (reviewed by (Icoz and Stotzky, 2008). More 694 
specifically, Cry3Bb1 of GM maize was found to be more rapidly degraded in soil compared to 695 
Cry1Ab under similar conditions (Baumgarte and Tebbe, 2005; Miethling-Graff et al., 2010).  696 
Considering the scope of the application (that excludes cultivation) and the intended uses of maize 697 
MON89034 x MON88017, it can be concluded that the exposure of potentially sensitive non-target 698 
organisms to the Cry1A.105, Cry2Ab2 and Cry3Bb1 proteins is likely to be very low and of no 699 
ecological relevance.  700 
6.1.2.5. Interactions with the abiotic environment and biogeochemical cycles 701 
Considering the scope of the application and the intended uses of maize MON89034 x MON88017 702 
and due to the low level of exposure to the environment, potential interactions with the abiotic 703 
environment and biogeochemical cycles were not considered an issue by the EFSA GMO Panel.  704 
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 705 
6.1.3. Post-market environment monitoring 706 
The objectives of a monitoring plan according to Annex VII of Directive 2001/18/EC are (1) to 707 
confirm that any assumption regarding the occurrence and impact of potential adverse effects of the 708 
GMO, or its use, in the environmental risk assessment are correct and (2) to identify the occurrence of 709 
adverse effects of the GMO, or its use, on human health or the environment which were not 710 
anticipated in the environmental risk assessment.  711 
Monitoring is related to risk management, and thus a final adoption of the monitoring plan falls 712 
outside the mandate of the EFSA GMO Panel. However, the EFSA GMO Panel gives its opinion on 713 
the scientific quality of the monitoring plan provided by the applicant (EFSA, 2006c). The potential 714 
exposure to the environment of maize MON89034 x MON88017 would be mainly through manure 715 
and faeces from the gastrointestinal tracts of animals fed maize MON89034 x MON88017 and/or 716 
through accidental release into the environment of viable GM maize grains during transportation and 717 
processing.  718 
No specific environmental impact of maize MON89034 x MON88017 was indicated by the 719 
environmental risk assessment and thus no case-specific monitoring is required.  720 
The general surveillance plan proposed by the applicant includes (1) the description of an approach 721 
involving operators (federations involved in maize import and processing), reporting to the applicants, 722 
via a centralised system, any observed adverse effect(s) of GMOs on human health and the 723 
environment, and (2) a coordinating system established by EuropaBio for the collection of the 724 
information recorded by the various operators (Lecoq et al., 2007, Windels et al., 2008); (3) the use of 725 
networks of existing surveillance systems. The applicant proposes a general surveillance report on an 726 
annual basis and a final report at the end of the consent. 727 
The EFSA GMO Panel is of the opinion that the scope of the monitoring plan provided by the 728 
applicant is in line with the intended uses of maize MON89034 x MON88017 since the environmental 729 
risk assessment does not cover cultivation and identified no potential adverse environmental effects. 730 
The EFSA GMO Panel agrees with the reporting intervals proposed by the applicant in the general 731 
surveillance plan.  732 
6.2. Conclusion 733 
The scope of the application includes food and feed uses, import and processing of maize MON89034 734 
x MON88017 and excludes cultivation. Considering the intended uses of maize MON89034 x 735 
MON88017, the environmental risk assessment is concerned with indirect exposure through manure 736 
and faeces from gastrointestinal tracts of animals fed maize MON89034 x MON88017 and with the 737 
accidental release into the environment of maize MON89034 x MON88017 grains during 738 
transportation and processing.  739 
There are no indications of an increased likelihood of establishment and spread of feral maize plants in 740 
case of accidental release into the environment of viable maize MON89034 x MON88017 grains 741 
during transportation and processing for food and feed uses, except in the presence of the herbicide. 742 
Taking into account the scope of the application, both the rare occurrence of feral maize plants and the 743 
low levels of Cry1A.105, Cry2Ab2, Cry3Bb1 protein exposure in maize MON89034 x MON88017 744 
grains or through other routes indicate that the risk to non-target organisms is considered extremely 745 
low.  746 
The scope of the monitoring plan provided by the applicant is in line with the intended uses of maize 747 
MON89034 x MON88017, since the environmental risk assessment did not cover cultivation and 748 
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identified no potential adverse environmental effects. Furthermore, the EFSA GMO Panel agrees with 749 
the reporting intervals proposed by the applicant in the general surveillance plan.  750 
OVERALL CONCLUSIONS AND RECOMMENDATIONS 751 
The EFSA GMO Panel was requested to carry out a scientific risk assessment of the maize 752 
MON89034 x MON88017 for food and feed uses, import and processing.  753 
The EFSA GMO Panel is of the opinion that the molecular characterisation data provided for maize 754 
MON89034 × MON88017 produced by conventional breeding are adequate to perform this part of the 755 
safety assessment. The bioinformatic analysis of the inserted DNA and the flanking regions of the 756 
single events MON89034 and MON88017 does not raise safety concerns. The expression of 757 
Cry1A.105, Cry2Ab2, Cry3Bb1 and CP4 EPSPS proteins in maize MON89034 × MON88017 has 758 
been sufficiently analysed and the stability of the genetic modification has been demonstrated. The 759 
EFSA GMO panel considers that the molecular characterisation does not indicate any safety concern. 760 
Based on the results of the comparative analysis it was concluded that maize MON89034 x 761 
MON88017 is compositionally and agronomically equivalent to its conventional counterpart and 762 
commercial non-GM maize varieties, except for the presence of Cry1A.105, Cry2Ab2, Cry3Bb1 and 763 
CP4 EPSPS proteins expressed in maize MON88017 x MON89034. Based on the assessment of data 764 
available, including the additional information provided by the applicant in response to the EFSA 765 
GMO Panel’s request, for maize MON89034 x MON88017, for the single events and for appropriate 766 
comparator(s), the EFSA GMO Panel has found no indication that crossing of MON89034 and 767 
MON88017 results in an interaction between the single events which causes compositional or 768 
agronomic changes. The Cry1A.105 and Cry2Ab2 proteins expressed in the parental maize 769 
MON89034 and the Cry3Bb1 and CP4 EPSPS proteins expressed in the parental maize MON88017 770 
have been assessed previously and no safety concerns were identified. Given all the information 771 
provided, the EFSA GMO Panel concludes that interactions between the single events that might 772 
impact on food and feed safety are unlikely and that the nutritional properties of maize MON89034 x 773 
MON88017 would not be different from those of its conventional counterpart and commercial non-774 
GM maize varieties. The EFSA GMO Panel considers that maize MON89034 x MON88017 is as safe 775 
and as nutritious as its conventional counterpart and commercial non-GM maize varieties and that the 776 
overall allergenicity of the whole plant is not changed. 777 
Considering the intended uses of maize MON89034 x MON88017, which exclude cultivation, there is 778 
no requirement for scientific assessment of potential environmental effects associated with the 779 
cultivation of this GM maize. In case of accidental release into the environment of viable maize 780 
MON89034 x MON88017 grains during transportation and processing, there are no indications of an 781 
increased likelihood of establishment and spread of feral maize plants, except in the presence of the 782 
herbicide. Also, the low levels of environmental exposure to these GM maize plants and the 783 
Cry1A.105, Cry2Ab2, Cry3Bb1 proteins through other routes indicate that the risk to non-target 784 
organisms is extremely low. The scope of the post-market environmental monitoring plan provided by 785 
the applicant is in line with the intended uses of maize MON89034 x MON88017.  786 
In conclusion, the EFSA GMO Panel considers that the information available for maize MON89034 x 787 
MON88017 addresses the scientific comments raised by the Member States and that the maize 788 
MON89034 x MON88017 as described in this application is as safe as its conventional counterpart 789 
with respect to potential effects on human and animal health and the environment in the context of its 790 
intended uses. The EFSA GMO Panel concludes that maize event MON89034 x MON88017 is 791 
unlikely to have any adverse effect on human and animal health and the environment, in the context of 792 
its intended uses. 793 
 794 
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DOCUMENTATION PROVIDED TO EFSA 795 
1. Letter from the Competent Authority of the MS, dated 12 February 2007, concerning a request for 796 
placing on the market of genetically modified MON89034 x MON88017 maize in accordance 797 
with Regulation (EC) No 1829/2003. 798 
2. Acknowledgement letter, dated 16 February 2007, from EFSA to the Competent Authority of the 799 
Netherlands.  800 
3. Letter from EFSA to applicant, dated 1 August 2007, requesting additional information under 801 
completeness check  802 
4. Letter from applicant to EFSA, dated 23 August 2007, providing additional information under 803 
completeness check.  804 
5. Letter from EFSA to applicant, dated 5 September 2007, requesting additional information under 805 
completeness check  806 
6. Letter from applicant to EFSA, dated 11 September 2007, providing additional information under 807 
completeness check.  808 
7. Letter from EFSA to applicant, dated 20 September 2007, delivering the ‘Statement of Validity’ 809 
for application EFSA-GMO-NL-2007-39, MON89034 x MON88017 maize submitted by 810 
MONSANTO under Regulation (EC) No 1829/2003. 811 
8. Letter from EFSA to applicant, dated 21 September 2007, requesting additional information and 812 
stopping the clock (JRC). 813 
9. Letter from applicant to EFSA, dated 26 September 2007, providing the additional copies for the 814 
valid version. 815 
10. Letter from EFSA to applicant, dated 23 October 2007, requesting additional information and 816 
stopping the clock (EFSA).  817 
11. Letter from applicant to EFSA, dated 10 December 2007, providing the Monitoring plan. 818 
12. Letter from EFSA to applicant, dated 8 January 2008, restarting the clock (JRC) and maintaining 819 
the clock stopped (EFSA). 820 
13. Letter from applicant to EFSA, dated 17 April 2008, providing spontaneously info (updated 821 
Monitoring plan). 822 
14. Letter from EFSA to applicant dated 19 November 2008, maintaining the clock stopped (3). 823 
15. Letter from EFSA to applicant, dated 15 November 2008, restarting the clock. 824 
16. Letter from EFSA to applicant, dated 18 December 2008, requesting additional information and 825 
stopping the clock (3).  826 
17. Letter from EFSA to applicant dated 8 April 2009, requesting additional information and 827 
maintaining the clock stopped (4). 828 
18. Letter from applicant to EFSA, dated 17 April 2009, providing the timeline for submission of 829 
response. 830 
19. Letter from EFSA to applicant dated 29 May 2009, requesting additional information and 831 
maintaining the clock stopped (5). 832 
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20. Letter from applicant to EFSA, dated 3 June 2009, providing additional information (requested by 833 
EFSA on 8th April).  834 
21. Letter from applicant to EFSA, dated 30 June 2009, providing additional information (requested 835 
by EFSA on 29 May).  836 
22. Letter from EFSA to applicant dated 30 June 2009, requesting additional information and 837 
maintaining the clock stopped (6). 838 
23. Letter from applicant to EFSA, dated 3 August 2009, providing the timeline for submission of 839 
response. 840 
24. Letter from applicant to EFSA, dated 18 August 2009, providing a new timeline for submission of 841 
response. 842 
25. Letter from applicant to EFSA, dated 8 September 2009, providing additional information 843 
(requested by EFSA on 30th June).  844 
26. Letter from EFSA to applicant, dated 15 October 2009, restarting the clock. 845 
27. Letter from EFSA to applicant, dated 5 November 2009, requesting additional information and 846 
stopping the clock (7).  847 
28. Letter from applicant to EFSA, dated 11 November 2009, providing additional information. 848 
29. Letter from EFSA to applicant, dated 11 January 2010, restarting the clock. 849 
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